Medpace trades as part of the medical diagnostics and research industry and is part of the healthcare sector. The company CEO is August J. Troendle. Medpace Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.
Previous Intraday Performance:
The MEDP shares had a previous change of 3.82% which opened at 54.31 and closed at 55.69. It moved to an intraday high of 55.72 and a low of 53.10.
Over the last five trading days, MEDP shares returned -0.50% and in the past 30 trading days it returned -2.88%. Over three months, it changed 1.27%. In one year it has changed 31.19% and within that year its 52 week high was 71.66 and its 52 week low was 41.27. MEDP stock is 34.94% above its 52 week low.
Our calculations result in a 200 day moving average of 57.54 and a 50 day moving average of 57.16. Right now, MEDP stock is trading -3.22% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
The company has a market cap of $2.0b with 35.7m shares outstanding and a float of 35.0m shares. Trading volume was 548,506 shares and has experienced an average volume of 405,318 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Medpace was 1.98 which ended on 31st of December 2018, which according to the previous close, that is a PE of 28.13. Based on 6 analyst estimates, the consensus EPS for the next quarter is 0.60. The trailing twelve month EPS reported is 2.64 (trailing twelve month diluted EPS is 2.09).
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr 2019||Reported 04-29-2019:||0.51|
|4th||Qtr 2018||Reported 02-25-2019:||0.61|
|3rd||Qtr 2018||Reported 10-29-2018:||0.52|
|2nd||Qtr 2018||Reported 07-30-2018:||0.45|
|1st||Qtr 2018||Reported 04-30-2018:||0.40|
Base on our calculations, the intrinsic value per share is 52.83, which means it might be overvalued by -5.40%.
The growth of the EPS is critical in understanding the current valuation of Medpace; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 55.40% over the last twelve months.
Indicators Also to Watch:
The beta was calculated to be 1.43.
SeekingAlpha: Standing At The Edge Of The Abyss
Based on last reported financials, the company’s return on assets is 8.19%, profit margin is 10.56%, price-to-sales is 2.58 and price-to-book is 3.09.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
4 : Financial Safety Result
4 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result